68Gallium PSMA-PET/CT for Bladder Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Bladder CancerPET/CT imaging - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if a 68Gallium PSMA PET/CT scan can better detect cancer in people with metastatic bladder cancer than the standard FDG-PET/CT scan.

Eligible Conditions
  • Bladder Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Define the proportion of patients with 1 or more lesions detectable by 68Gallium PSMA-PET/CT

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

68Gallium PSMA-PET/CT
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: 68Gallium PSMA-PET/CT · No Placebo Group · Phase 1

68Gallium PSMA-PET/CTExperimental Group · 2 Interventions: PET/CT imaging, [68Ga]PSMA · Intervention Types: DiagnosticTest, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT imaging
2016
Completed Phase 3
~410

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,528 Total Patients Enrolled
Gopakumar IyerPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patient must be able to understand and is willing to sign a written informed consent document.